지니너스
Financials
Valuation Metrics
지니너스's Market Cap is ₩762B. At end of 2025 it was ₩1379B. Ranked #1465 of 2,421 in KR market (top 61%), #847 of 1,640 on KOSDAQ (top 52%), #156 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 68%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 76.18B KRW | KR#1,465/2,421 Sec#156/231 |
| Revenue | 11.28B KRW | KR#2,274/2,421 Sec#172/231 |
| Net Income | -20.36B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 54.56B KRW | KR#2,164/2,421 Sec#192/231 |
| Net Assets | 40.68B KRW | KR#2,036/2,421 Sec#179/231 |
| Employees | 73 | KR#1,853/2,421 Sec#159/231 |
| Value | ||
| P/B | 1.87x | KR#1,901/2,421 Sec#141/231 |
| P/S | 6.76x | KR#2,212/2,421 Sec#151/231 |
| FCF Yield | -11.05% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -50.04% | KR#2,277/2,421 Sec#196/231 |
| ROA | -37.31% | KR#2,343/2,421 Sec#210/231 |
| Op. Margin | -105.77% | KR#2,306/2,421 Sec#175/231 |
| Revenue Growth | 33.88% | KR#341/2,421 Sec#35/231 |
| Financial Health | ||
| Debt Ratio | 34.13% | KR#668/2,421 Sec#77/231 |
| Total Debt | 6.76B KRW | KR#1,735/2,421 Sec#162/231 |
| FCF | -8.42B KRW | KR#1,656/2,421 Sec#139/231 |
| Cash | 13.57B KRW | KR#1,500/2,421 Sec#121/231 |
| Current Ratio | 3.11x | KR#535/2,421 Sec#75/231 |
| Performance | ||
| 1Y Return | -4.96% | KR#836/2,421 Sec#51/231 |
| 1M Return | -5.66% | KR#1,844/2,421 Sec#148/231 |
| From 52W High | -70.15% | KR#2,193/2,421 Sec#190/231 |
| 1Y MDD | -73.08% | KR#2,109/2,421 Sec#185/231 |
| Trading | ||
| Volume | 151,074 shares | KR#588/2,421 Sec#44/231 |
| Trading Value | 298.4M KRW | KR#1,129/2,421 Sec#115/231 |
| Foreign Own. | 3.84% | KR#1,084/2,421 Sec#98/231 |
| Per Share | ||
| EPS | -517 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,033 KRW | KR#2,301/2,421 Sec#210/231 |
Company Info
Spun off from Samsung Genome Research Institute in 2018, this bio venture specializes in genome analysis and solution development. It offers NGS-based cancer genome diagnostic solution CancerSCAN, single-cell analysis platform Celinus, and cloud-based spatial omics analysis solution SPACEINSIGHT. The company is advancing new businesses like AI-based new drug development and digital pathology-based companion diagnostic solutions, while collaborating with domestic and international pharmaceutical companies using its single-cell and spatial omics analysis technologies.